Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Hims’s acquisition of Trybe Labs will put it in competition with health industry juggernauts such as Labcorp and Quest ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 24.8% in the afternoon session after the company announced the acquisition of Sigmund (marketed as Trybe Labs), which will allow it ...

Short sellers, who bet on stock prices falling, have had a tough start to 2025. In fact, they have lost a staggering $73 billion in the U.S.

In this article, we are going to take a look at where Hims & Hers Health Inc. (NYSE:HIMS) stands against other firms that posted double-digit gains on Thursday. Wall Street’s main indices ...